Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT/QTc evaluation study of TS-172 in healthy adult subjects
jRCT2071240113Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TS-172 in hyperphosphatemia (4 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: QTcF change in Holter ECGs. Started Mar 2025; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on jRCT2071240113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240113.